Tag Archives: Oren Livnat

BioDelivery (BDSI) Receives a Buy from H.C. Wainwright

H.C. Wainwright analyst Oren Livnat maintained a Buy rating on BioDelivery (BDSI – Research Report) today and set a price target of $6. The company’s shares closed yesterday at $4.62. Livnat noted: “Our $6 12-month target (from $5) is based

Analysts Offer Insights on Healthcare Companies: Aerie Pharma (NASDAQ: AERI), Neurocrine (NASDAQ: NBIX) and Homology Medicines Inc (NASDAQ: FIXX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Aerie Pharma (AERI – Research Report), Neurocrine (NBIX – Research Report) and Homology Medicines Inc (FIXX – Research Report) with bullish sentiments.

Lipocine (LPCN) Receives a Buy from H.C. Wainwright

In a report released today, Oren Livnat from H.C. Wainwright maintained a Buy rating on Lipocine (LPCN – Research Report), with a price target of $3. The company’s shares closed on Friday at $2.06. According to TipRanks.com, Livnat is a

Antares Pharma (ATRS) Received its Third Buy in a Row

After Jefferies and Raymond James gave Antares Pharma (NASDAQ: ATRS) a Buy rating last month, the company received another Buy, this time from H.C. Wainwright. Analyst Oren Livnat maintained a Buy rating on Antares Pharma today and set a price

Analysts Are Bullish on These Healthcare Stocks: Agile Therapeutics (AGRX), NovaBay Pharma (NBY)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Agile Therapeutics (AGRX – Research Report), NovaBay Pharma (NBY – Research Report) and Avenue Therapeutics Inc (ATXI – Research Report) with bullish

H.C. Wainwright Believes Antares Pharma (NASDAQ: ATRS) Won’t Stop Here

H.C. Wainwright analyst Oren Livnat reiterated a Buy rating on Antares Pharma (ATRS – Research Report) today and set a price target of $4.50. The company’s shares closed yesterday at $3.61, close to its 52-week high of $3.93. Livnat said: